Recent developments and emerging directions in ion chromatography

PR Haddad, PN Nesterenko, W Buchberger - Journal of Chromatography A, 2008 - Elsevier
This review provides a selected overview of some of the significant developments that have
occurred in ion chromatography (IC) over recent years, together with some views on the …

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

S Leijen, SA Burgers, P Baas, D Pluim, M Tibben… - Investigational new …, 2015 - Springer
Summary Background This phase I/II study determined the maximal tolerable dose, dose
limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of …

Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: a review

S Cohen, LP Jordheim, M Megherbi… - … of Chromatography B, 2010 - Elsevier
Endogenous ribonucleotides and deoxyribonucleotides play a crucial role in cell function.
The determination of their levels is of fundamental interest in numerous applications such as …

Nucleotide and nucleotide sugar analysis by liquid chromatography-electrospray ionization-mass spectrometry on surface-conditioned porous graphitic carbon

M Pabst, J Grass, R Fischl, R Leonard, C Jin… - Analytical …, 2010 - ACS Publications
We examined the analysis of nucleotides and nucleotide sugars by chromatography on
porous graphitic carbon with mass spectrometric detection, a method that evades …

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

SP Blagden, I Rizzuto, P Suppiah, D O'Shea… - British journal of …, 2018 - nature.com
Background Gemcitabine is used to treat a wide range of tumours, but its efficacy is limited
by cancer cell resistance mechanisms. NUC-1031, a phosphoramidate modification of …

Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma

SD Stoker, Z Novalić, MA Wildeman… - Journal of cancer …, 2015 - Springer
Purpose Despite successful primary treatment of nasopharyngeal carcinoma (NPC), the
incidence of distant metastasis remains 25–34%. Treatment options are limited, and survival …

Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study

SA Veltkamp, RS Jansen, S Callies, D Pluim… - Clinical cancer …, 2008 - AACR
Purpose: To determine the toxicity, tolerability, pharmacokinetics, pharmacodynamics, and
preliminary antitumor activity of oral gemcitabine (2′, 2′-difluorodeoxycytidine; dFdC) in …

A novel method for quantification of gemcitabine and its metabolites 2′, 2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS …

TE Bapiro, FM Richards, MA Goldgraben… - Cancer chemotherapy …, 2011 - Springer
Purpose To develop a sensitive analytical method to quantify gemcitabine (2′, 2′-
difluorodeoxycytidine, dFdC) and its metabolites 2′, 2′-difluorodeoxyuridine (dFdU) and …

Analysis of mononucleotides by tandem mass spectrometry: investigation of fragmentation pathways for phosphate-and ribose-modified nucleotide analogues

D Strzelecka, S Chmielinski, S Bednarek, J Jemielity… - Scientific Reports, 2017 - nature.com
Synthetic nucleotide and nucleic acid analogues are useful research tools and modern
therapeutics. Hence, methods for the rapid and unambiguous identification of …

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′, 2′‐difluorodeoxyuridine and their nucleotides

EJB Derissen, ADR Huitema, H Rosing… - British journal of …, 2018 - Wiley Online Library
Aims Gemcitabine (2′, 2′‐difluoro‐2′‐deoxycytidine; dFdC) is a prodrug that has to be
phosphorylated within the tumour cell to become active. Intracellularly formed gemcitabine …